The Rebif® New Formulation Story: It's Not Trials and Error

ISSN： 1174-5886

Source： Drugs in R&D, Vol.8, Iss.6, 2007-01, pp. : 335-348

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics of a New Orodispersible Tablet Formulation of Vardenafil: Results of Three Clinical Trials

By Heinig Roland

Clinical Drug Investigation, Vol. 31, Iss. 1, 2011-01 ,pp. : 27-41

Adis International

Access to resources Recommend Favorite

The Adjustment of the Type I Error Rate in Noninferiority Trials with -Margin Approach: Each of Two Different New Drugs is Approved with Two Independent Trials with the Same Active Control

By Kang Seung-Ho Ryu Yuman

Journal of Biopharmaceutical Statistics, Vol. 21, Iss. 3, 2011-05 ,pp. : 498-510

Taylor & Francis Ltd

Access to resources Recommend Favorite

EVIDENCE of lower relapse rate with `Rebif'

Inpharma, Vol. 1, Iss. 1342, 2002-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

New mesalazine formulation advantageous in IBD

Inpharma, Vol. 1, Iss. 1286, 2001-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Subcutaneous Interferon-β-1a: New Formulation

By McKeage Kate Wagstaff Antona J.

CNS Drugs, Vol. 21, Iss. 10, 2007-01 ,pp. : 871-876

Adis International

Access to resources Recommend Favorite